683 Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

683 Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.1M	Sell	90,000 -9,000	-9%	-$4.3M	2.46%	6
2025 Q4	$57.7M	Sell	99,000 -53,000	-35%	-$27.1M	2.51%	8
2025 Q3	$69.7M	Hold	152,000	–	–	3.64%	4
2025 Q2	$46M	Hold	152,000	–	–	3.02%	8
2025 Q1	$50.3M	Sell	152,000 -2,500	-2%	-$821K	3.47%	5
2024 Q4	$47.7M	Buy	154,500 +143,000	+1,243%	+$40.2M	2.95%	4
2024 Q3	$2.44M	Hold	11,500	–	–	0.19%	85
2024 Q2	$3.22M	Sell	11,500 -166,400	-94%	-$39.6M	0.24%	75
2024 Q1	$47.5M	Buy	177,900 +167,900	+1,679%	+$39.6M	3.48%	5
2023 Q4	$2.31M	Hold	10,000	–	–	0.19%	76
2023 Q3	$1.46M	Sell	10,000 -25,000	-71%	-$4.71M	0.11%	93
2023 Q2	$8.09M	Hold	35,000	–	–	0.58%	47
2023 Q1	$8.48M	Buy	+35,000	New	+$9.54M	0.63%	47

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's MDGL Position: Q3 2025 in Review

683 Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 24,865 shares — an estimated $9.28M sold.

683 Capital Management first reported a position in MDGL in Q4 2024 and held it in 3 quarters. The position peaked at $7.81M in Q1 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

683 Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
683 Capital Management sold 24,865 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $9.28M.
683 Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 3 quarters.
683 Capital Management's Madrigal Pharmaceuticals position peaked at $7.81M in Q1 2025.
352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on 683 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.